Comparison of the efficacy of tadalafil in three different groups: patients on hemodialysis, first kidney transplant recipients, and second kidney transplant recipients

Article Type:
Research/Original Article (دارای رتبه معتبر)

The efficacy of phosphodiesterase-5 inhibitors (PDE5Is) on the improvement of erectile dysfunction (ED) in second kidney transplant (KT) recipients has not been well investigated previously.


We aimed to compare the efficacy of tadalafil in three groups: hemodialysis (HD) patients, first KT recipients (KT1), and second KT recipients (KT2) with bilaterally ligated internal iliac arteries.


Age-matched men with erectile dysfunction were included in the study. Patients were divided into three groups: HD, KT1, and KT2. The International Index of Erectile Function 15 (IIEF-15) was used to assess baseline erectile function. Tadalafil was administered in a dose-escalation method for three months. Patients were reevaluated by the questionnaire at three months. The mean score evolution was compared between the study groups by one-way ANOVA.


The final analysis included 106 patients in three groups. There was no significant difference between the study groups regarding age, body mass index (BMI), blood pressure, and frequency of smoking, opium, or alcohol use. Tadalafil was safe and effective in all three groups. The mean IIEF score evolution in HD, KT1, and KT2 groups was 16.4 (58.7% increase from baseline), 19.3 (45.0% increase), and 20.4 (52.7% increase), respectively (P= 0.66).


Tadalafil is effective and safe in managing ED after the second kidney transplantation, where the internal iliac arteries are cut bilaterally. The response rate is similar to first kidney transplant recipients and hemodialysis patients.

International Journal of Organ Transplantation Medicine, Volume:14 Issue: 1, Winter 2023
28 to 34  
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یک‌ساله به مبلغ 1,390,000ريال می‌توانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
  • حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران می‌شود.
  • پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانه‌های چاپی و دیجیتال را به کاربر نمی‌دهد.
In order to view content subscription is required

Personal subscription
Subscribe for 70 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!